(19)
(11) EP 4 823 681 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24821818.2

(22) Date of filing: 09.12.2024
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
C07K 16/28(2006.01)
A61P 37/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 2317/76; C07K 16/2875; A61P 37/00; A61P 35/00; C07K 2317/21; C07K 2317/92; C07K 2317/52; C07K 2317/33; C07K 2317/24
(86) International application number:
PCT/EP2024/085230
(87) International publication number:
WO 2025/125137 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 11.12.2023 US 202363608374 P

(71) Applicant: GlaxoSmithKline Intellectual Property Development Ltd
Stevenage SG1 2NY (GB)

(72) Inventors:
  • AHMED, Farheen
    Stevenage SG1 2NY (GB)
  • ORECCHIA, Martin
    Stevenage SG1 2NY (GB)
  • OVECKA, Milan
    Stevenage SG1 2NY (GB)

(74) Representative: Shepherd, Marianne Elizabeth Araxi 
GSK Legal & Compliance - Global Patents 79 New Oxford Street
London WC1A 1DG
London WC1A 1DG (GB)

   


(54) BAFF SPECIFIC ANTIBODIES